Empagliflozin 25 MG Clinical Trials
12 recruitingDrug
Phase 14Phase 43Early Phase 12Not Applicable2Phase 31Phase 21
Showing 1–12 of 12 trials
Recruiting
Phase 3
meChANisms and sAfety of SGLT2 Inhibition in peRitoneal dialYsis
Peritoneal Dialysis Complication
University Health Network, Toronto20 enrolled1 locationNCT05715814
Recruiting
Early Phase 1
SGLT2 Inhibitors, Ketones, and Cardiovascular Benefit Research Plan
Heart Failure With Preserved Ejection FractionType2 Diabetes
The University of Texas Health Science Center at San Antonio30 enrolled1 locationNCT05057806
Recruiting
Phase 4
Effects of the SGLT2 Inhibitor Empagliflozin in Patients With Euvolemic and Hypervolemic Hyponatremia
University Hospital, Basel, Switzerland172 enrolled6 locationsNCT04447911
Recruiting
Early Phase 1
SGLT2i, Hepatic Glucose Production, and SNS
Type 2 Diabetes
The University of Texas Health Science Center at San Antonio22 enrolled1 locationNCT07053293
Recruiting
Phase 1
SGLT2i, Ketoacidosis, Volume Contraction, and Insulinopenia
Type 2 Diabetes
The University of Texas Health Science Center at San Antonio29 enrolled1 locationNCT07053306
Recruiting
Phase 1
SGLTi, Hepatic Glucose Production and Ketogenesis
Type 2 Diabetes
The University of Texas Health Science Center at San Antonio30 enrolled1 locationNCT05960656
Recruiting
Phase 1Phase 2
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
ObesityMetabolic Syndrome
Vanderbilt University Medical Center74 enrolled1 locationNCT05972564
Recruiting
Not Applicable
Adipose Tissue Heterogeneity and Its Link to Type 2 Diabetes
Type 2 Diabetes
Karolinska Institutet60 enrolled1 locationNCT05501483
Recruiting
Phase 4
EMPAgliflozin in Heart Failure With PReserved Ejection Fraction and End Stage Renal Disease
End Stage Renal Disease on DialysisHeart Failure With Preserved Ejection Fraction
National Taiwan University Hospital150 enrolled2 locationsNCT06249945
Recruiting
Phase 4
Empagliflozin in Heart Failure with Reduced Ejection Fraction and End Stage Renal Disease
National Taiwan University Hospital95 enrolled2 locationsNCT06249932
Recruiting
Not Applicable
Effect of Empagliflozin vs Linagliptin on Glycemic Outcomes,Renal Outcomes & Body Composition in Renal Transplant Recipients With Diabetes Mellitus
Diabetes MellitusKidney Transplant; Complications
Medanta, The Medicity, India200 enrolled1 locationNCT06095492
Recruiting
Phase 1
To Evaluate the Safety and Pharmacokinetic Interaction Between HODO-22251 and HODO-22252 in Healthy Adults
Type 2 DiabetesDyslipidemias
Hyundai Pharm56 enrolled1 locationNCT06578676